GB2456907A — Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.

USPTO Abstract

A method, particularly a diagnostic method, for determining subsequent vandetanib therapy, either alone or in combination with another therapy, for a human patient, comprising obtaining a fluid sample from a patient prior to treatment with vandetanib, measuring the level of VEGF in the fluid sample (baseline VEGF); determining whether the baseline VEGF is equal to or less than, or above a threshold VEGF level; and thereby determining whether the patient is likely to receive clinical benefit from vandetanib therapy either alone or in combination with another therapy. The level of VEGF can be measured by immunoassay such as ELISA. The fluid sample may be whole blood, a blood derivative, serum or plasma. The patient may have or may be suspected of having non-small-cell lung cancer (NSCLC), thyroid cancer or thyroid cancer such as medullary cancer.